EWM
KPTI icon

Endurance Wealth Management’s Karyopharm Therapeutics KPTI Stock Holding History

Endurance Wealth Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,067
Closed -$171K – 512
2016
Q4 		$150K Hold
1,067
– – 0.03% 190
2016
Q3 		$156K Buy
1,067
+667
+167% +$80.2K 0.03% 186
2016
Q2 		$40K Hold
400
– – 0.01% 280
2016
Q1 		$54 Hold
400
– – 0.01% 252
2015
Q4 		$80K Hold
400
– – 0.02% 230
2015
Q3 		$69K Buy
400
+267
+201% +$71.4K 0.01% 242
2015
Q2 		$54K Buy
+133
New +$57.5K 0.01% 260

Other funds holding KPTI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

Endurance Wealth Management's KPTI Position: Q1 2017 in Review

Endurance Wealth Management sold out of Karyopharm Therapeutics (KPTI) in Q1 2017, closing a stake of 1,067 shares — an estimated $171K sold.

Endurance Wealth Management first reported a position in KPTI in Q2 2015 and held it in 7 quarters. The position peaked at $156K in Q3 2016. 80 funds tracked by Wall St. Rank hold KPTI as of Q1 2017.

  • Endurance Wealth Management reported no remaining Karyopharm Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Endurance Wealth Management sold 1,067 Karyopharm Therapeutics shares in Q1 2017, an estimated $171K.
  • Endurance Wealth Management first reported a position in Karyopharm Therapeutics in Q2 2015 and held it in 7 quarters.
  • Endurance Wealth Management's Karyopharm Therapeutics position peaked at $156K in Q3 2016.
  • 80 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2017.

Based on Endurance Wealth Management's 13F filing for Q1 2017, filed 5 May 2017.